The United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) have issued a Federal Register Notice announcing a joint public listening session and requesting written comments on areas for collaboration and engagement between the agencies.
The USPTO proposed collaboration initiatives in a July 6 letter to the FDA. These initiatives aim to enhance collaboration between the USPTO and the FDA to ensure that our innovation system strikes the appropriate balance—encouraging meaningful innovation in drug development and supporting a competitive marketplace that can promote greater access to medicines for American families. To facilitate stakeholder feedback on these initiatives, this notice sets forth questions on various collaboration topics.
- Recording of public listening session part 1
- Recording of public listening session part 2
If you have any questions, please contact Starr Baker (email@example.com).
Registration for this event is closed.
The listening session will be recorded, and a recording and transcript will be posted here a few weeks after the event.
Read the full text of the notice on the USPTO-FDA collaboration initiatives webpage. Information about the collaborative efforts can be read in the USPTO’s joint blog with the FDA.
If you are an individual with a disability and would like to request a reasonable accommodation, please submit your request to the contact information listed above.